Replies to post #42405 on Biotech Values

[DewDiligence]

>why wouldn't ANDS just take the hit on it now? Get it over with? That seems to make more sense than a constant bleed .........and then a hit?<

The same question could be asked of many development-stage biotechs. For instance, why did GENR mislead investors for two years before finally admitting that the Evizon program in AMD was not viable?

The answer, of course, is Zebra’s Law (#msg-5915520).

I’m not certain that ANA380 is dead, but I do think the evidence is pointing strongly in that direction. Regards, Dew

p.s. ANDS is down 11% today; presumably, other investors have reached a similar conclusion.